TroVax Statement

Statement regarding TroVax and the TRIST and QUASAR V studies

Our understanding of the Data Safety Monitoring Board’s recommendations issued in relation to the TRIST study in renal cancer does not impact on our enthusiasm to progress the QUASAR V TroVax study in adjuvant colorectal cancer.  From both a scientific and clinical perspective we feel that TroVax should be tested in the adjuvant setting of colorectal cancer and remain committed to the study.

Professor David Kerr and Dr Rachel Midgley
OCTO banner

University of Oxford Crest

Department of
Clinical Pharmacology